EGFR antagonist antibodyBoxed warning: Dermatologic toxicityIndian prescription status not found in lists checkedJan Aushadhi listed
Panitumumab
पानिटुमुमाब
This page covers the injection (intravenous) form only, as described in the US label. Other forms of panitumumab sold in India may differ.
Panitumumab is an antibody medicine given by intravenous infusion for certain adults with metastatic colorectal cancer. Its label carries a boxed warning for serious skin reactions, which affected most people in trials. It is used only under specialist cancer care.
- Generic name
- Panitumumab
- Used for
- Treating certain advanced bowel cancers (metastatic colorectal cancer) with specific tumour gene features.
- Label used
- Injection label, intravenous, DailyMed set e0fa4bca, effective 2026-06
- Prescription status (India)
- Not found in the Schedule H/H1/X/G lists we checked
- On NLEM 2022
- Not found in the list we checked
- NPPA price ceiling
- Not listed in the lists we checked
More facts
- Jan Aushadhi
- Listed (2 product rows)
- Banned combinations
- None found in the list we checked
Compiled from official drug labels and Indian government sources. Always follow your doctor's or pharmacist's advice.
Safety at a glance
- AlcoholNot mentioned in label text
- PregnancyNot mentioned in label text
- BreastfeedingCaution in label textSee wording
- DrivingNot mentioned in label text
- KidneyCaution in label textSee wording
- LiverNot mentioned in label text
Taken only from the label text cited on this page. "Not mentioned" does not mean safe. Ask your doctor or pharmacist.
What is panitumumab used for?
The label describes panitumumab as an EGFR antagonist for adults with metastatic colorectal cancer whose tumours are RAS wild-type. It may be given with FOLFOX chemotherapy first, or alone after other chemotherapy has stopped working.
It is also described for KRAS G12C-mutated disease together with sotorasib. The label says it is not for RAS-mutant disease outside that combination.
- Metastatic colorectal cancer, RAS wild-type, with FOLFOX
- Alone after earlier chemotherapy has failed
- With sotorasib for KRAS G12C-mutated disease
It treats certain advanced bowel cancers, chosen by tumour gene testing.
Source1
How does panitumumab work?
Panitumumab blocks the EGFR protein, which sits on the surface of cells and helps them grow. The label notes EGFR is overactive in some colon and rectal cancers.
Blocking it is meant to slow the growth signals in the tumour. The same protein is found in skin, which is why skin effects are common.
It blocks a growth signal that some bowel cancer cells depend on.
Source1
How is panitumumab usually taken?
This page covers the injection label only (route: intravenous). Dosing for other forms differs, and the prescriber decides which one you use.
This is label-level information, not personal advice. Indian pack labels may differ, and your prescriber's instruction always comes first.
This page covers the intravenous infusion form. It is given in a clinic or hospital, not taken at home.
For adults, the label describes an infusion every 14 days, given over about 60 to 90 minutes depending on the amount. Treatment continues until the disease progresses or side effects become unacceptable.
The label describes testing the tumour for RAS (or KRAS G12C) before starting. Medical resources for severe infusion reactions should be available.
- Given as a drip into a vein by trained staff
- Tumour gene test is done first
- Infusion rate may be slowed or stopped for reactions
It is given as a drip in a hospital every two weeks, after a tumour gene test.
Source1
What are the side effects of panitumumab?
Common
- The label lists skin rash, nail-fold infection (paronychia), tiredness, nausea and diarrhoea as common. With chemotherapy, mouth sores, low magnesium and low potassium are also common.
- Skin rash, dry skin, itching
- Nail infection around the nails
- Diarrhoea and mouth sores
- Tiredness
- Low magnesium or potassium
Serious: get help
- Serious effects include severe skin and soft tissue reactions, infusion reactions, kidney failure, lung scarring, eye problems and low electrolytes.
Skin rash is very common and can be severe.
Source1
Who should be careful with panitumumab?
The boxed warning says skin toxicity occurred in about 90% of people on its own and was severe in about 15%. Sun exposure should be limited.
The label describes no benefit, and possibly harm, in RAS-mutant disease outside the sotorasib use. It can harm an unborn baby; effective contraception is advised during treatment and for 2 months after the last dose.
The label lists no contraindications. Increased deaths were seen when combined with bevacizumab and chemotherapy.
- Boxed warning: severe skin toxicity
- Limit sun exposure
- Eye and lung problems need prompt review
- Can harm an unborn baby
- Not for RAS-mutant disease (except with sotorasib)
Serious skin reactions are the main warning, and it can harm a pregnancy.
Source1
What medicines interact with panitumumab?
- Bevacizumab plus chemotherapy: more toxicity
- Oxaliplatin chemotherapy in RAS-mutant tumours: worse outcomes
- The label we reviewed does not have a drug interactions section.
- It does warn about increased deaths and toxicity when used with bevacizumab and chemotherapy, and about oxaliplatin-based chemotherapy in RAS-mutant disease.
No match in this label text. Ask your pharmacist about any medicine you take.
Combining it with bevacizumab raised deaths and toxicity in trials.
Source1
How should panitumumab be stored?
The label gives a storage range of 2 to 8 degrees C.
The label also says to protect it from light.
Follow the storage line on your own pack, and keep medicines out of the reach of children.
Follow the storage instructions on your pack.
Source1
Is panitumumab a prescription medicine in India?
We did not find panitumumab in the Drugs Rules 1945 Schedule H, H1, X or G rows we checked, so we cannot state its Indian prescription status from our lists. Ask your pharmacist or doctor.
We did not find panitumumab on the National List of Essential Medicines 2022 in the list we checked.
The Jan Aushadhi (PMBJP) list we checked has 2 product rows that mention panitumumab. We did not capture prices for them.
We did not find panitumumab in the Schedule H, H1, X or G rows we checked, not found on NLEM 2022.
Source2
What is the price ceiling for panitumumab?
Jan Aushadhi lists panitumumab products including Panitumumab 100mg Infusion 100mg; Panitumumab 400mg Infusion 400mg. We have not shown a price for them. Check the pack and the seller for the actual price.
NPPA lists per-unit ceilings where a formulation is scheduled. Check the pack and seller.
Source2
Frequently asked questions
Can I drink alcohol while taking panitumumab?
The label we reviewed does not say. Ask your doctor or pharmacist.
Source1
Is panitumumab safe in pregnancy and breastfeeding?
The label says it can cause fetal harm. Contraception is advised during treatment and for 2 months after. Ask your doctor or pharmacist about breastfeeding.
Source1
Should panitumumab be taken with food?
It is given by infusion, so food timing is not relevant. The label we reviewed does not describe food effects. Ask your doctor or pharmacist.
Source1
Can panitumumab affect driving or alertness?
The label we reviewed does not say. Ask your doctor or pharmacist.
Source1
Can children or older adults take panitumumab?
The label we reviewed describes use in adults. It does not describe use in children. Ask your doctor or pharmacist.
Source1
Is panitumumab on the NLEM and Jan Aushadhi list?
We did not find it on NLEM 2022. Yes, several panitumumab products are in the Jan Aushadhi list we checked.
Source2
Sources
- 1U.S. FDA-approved label (DailyMed) (e0fa4bca-f245-4d92-ae29-b0c630a315c2) Open source · 2026-10-15
- 2PMBJP (Jan Aushadhi) product list (p84:sno1829) Open source · 2026-10-15
Compiled by software from the sources above and checked by automated rules. Last checked: 2026-10-15 · How we use sources · Report a correction
This information is educational and is not a substitute for advice from your doctor or pharmacist. It does not tell you what dose you personally should take. In an emergency call 112.